Persistent Microbial Peptidoglycan Drives Post-Infectious Autoimmunity in Lyme Disease 2265902
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Xin Chen und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Persistent symptoms after infection remain a major clinical challenge, yet their immunopathogenesis is poorly understood. Post-Treatment Lyme Disease (PTLD) affects over one million individuals in the United States and is characterized by fatigue, pain, and cognitive dysfunction despite antibiotic clearance of Borrelia burgdorferi. We hypothesized that peptidoglycan–bacterial cell wall remnants that can persist in the host after antibiotic treatment–sustain inflammation and trigger autoimmune-like responses.
Methods
Peripheral immune cells from PTLD patients and healthy controls fro two clinical cohorts were profiled using single-cell RNA-sequencing analysis. To determine causality, monocytes and human spleen organoids from healthy donors were stimulated with peptidoglycan from Borrelia burgdorferi (PGBb) or from other autoimmune-associated bacterial species. Cellular activation, cytokine secretion, and autoreactive B-cell responses were assessed by flow cytometry, ELISA, and gene expression analysis.
Results
PTLD patients exhibited an expanded hyperinflammatory monocyte subset expressing autoimmune-associated transcriptional and metabolic programs, along with other immune features characteristic of classical autoimmune diseases. Stimulation of healthy monocytes with PGBb recapitulated these features and induced a distinct proinflammatory cytokine profile. In human spleen organoids, PGBb activated autoreactive B cells and triggered gene expression programs linked to autoimmunity across multiple immune subsets. Peptidoglycans from bacteria associated with rheumatoid arthritis also elicited proinflammatory responses, revealing a conserved yet context-specific mechanism of peptidoglycan-driven autoimmunity.
Conclusion
Persistent peptidoglycans drive chronic inflammation and may promote autoimmunity in PTLD and related diseases, shaped by species-specific microbial contexts. This work also establishes human spleen organoids as a robust platform for studying autoimmune mechanisms following infection. Funding Source NIH, HHMI, Bill and Melinda Gates Foundation Topic Categories Immune Mechanisms of Human Disease (HUM)
Zitieren
APA
Chen, X., Zhou, X., Wang, H., Ji, X., Rebman, A., Pandit, M., Sola, E., Mengwasser, K., Salehi, A., Soloski, M., Snyder, M., Jacobs-Wagner, C., Robinson, W., Aucott, J., & Davis, M. (2026). Persistent Microbial Peptidoglycan Drives Post-Infectious Autoimmunity in Lyme Disease 2265902. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1083
Vancouver
Chen X, Zhou X, Wang H, Ji X, Rebman A, Pandit M, et al. Persistent Microbial Peptidoglycan Drives Post-Infectious Autoimmunity in Lyme Disease 2265902. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1083
BibTeX
@article{Chen2026,
author = {Chen, Xin and Zhou, Xin and Wang, Haozhen and Ji, Xihuai and Rebman, Alison and Pandit, Mahesh and Sola, Elsa and Mengwasser, Kristen and Salehi, Ahamd and Soloski, Mark and Snyder, Michael and Jacobs-Wagner, Christine and Robinson, William and Aucott, John and Davis, Mark},
title = {Persistent Microbial Peptidoglycan Drives Post-Infectious Autoimmunity in Lyme Disease 2265902},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1083}
}
EUVIMED